U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C14H19NO2.ClH
Molecular Weight 269.767
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHYLPHENIDATE HYDROCHLORIDE

SMILES

Cl.[H][C@@]1(CCCCN1)[C@H](C(=O)OC)C2=CC=CC=C2

InChI

InChIKey=JUMYIBMBTDDLNG-OJERSXHUSA-N
InChI=1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H/t12-,13-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C14H19NO2
Molecular Weight 233.3062
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Methylphenidate is a CNS stimulant approved for the treatment of narcolepsy and attention deficit hyperactivity disorder. The drug is believed to bind the dopamine transporter in the presynaptic cell membrane, thereby blocking the reuptake of dopamine and causing an increase in extracellular dopamine levels.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q01959
Gene ID: 6531.0
Gene Symbol: SLC6A3
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RITALIN

Approved Use

Ritalin is indicated for the treatment of Attention Deficit Disorders and Narcolepsy.

Launch Date

1955
Primary
RITALIN

Approved Use

Ritalin is indicated for the treatment of Attention Deficit Disorders and Narcolepsy.

Launch Date

1955
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.7 ng/mL
18 mg single, oral
dose: 18 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHYLPHENIDATE HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
41.8 ng × h/mL
18 mg single, oral
dose: 18 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHYLPHENIDATE HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.5 h
18 mg single, oral
dose: 18 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHYLPHENIDATE HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
90%
unknown, unknown
METHYLPHENIDATE HYDROCHLORIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
700 mg multiple, oral
Studied dose
unhealthy, 45 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 45 years
Sex: M
Population Size: 1
Sources:
Other AEs: Abuse...
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Other AEs: Hypertension, Tachycardia...
Other AEs:
Hypertension (grade 1)
Tachycardia (grade 1)
Confusion
Irritability
Agitation
Hallucinations
Sources:
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Disc. AE: Headache, Nausea...
AEs leading to
discontinuation/dose reduction:
Headache (1.6%)
Nausea (1.6%)
Hot flushes (1.6%)
Panic attack (1.6%)
Nausea (1.6%)
Vomiting (1.6%)
Dizziness (1.6%)
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Disc. AE: Fatigue, Lethargy...
AEs leading to
discontinuation/dose reduction:
Fatigue (1.5%)
Lethargy (1.5%)
Hypomania (1.5%)
Anger (1.5%)
Anxiety (1.5%)
Migraine (1.5%)
Depression (1.5%)
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
AEs

AEs

AESignificanceDosePopulation
Abuse
700 mg multiple, oral
Studied dose
unhealthy, 45 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 45 years
Sex: M
Population Size: 1
Sources:
Agitation
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Confusion
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Hallucinations
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Irritability
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Hypertension grade 1
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Tachycardia grade 1
210 mg 1 times / day single, oral
Studied dose
Dose: 210 mg, 1 times / day
Route: oral
Route: single
Dose: 210 mg, 1 times / day
Sources:
unhealthy, 8 years
n = 1
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: 8 years
Sex: F
Population Size: 1
Sources:
Dizziness 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Headache 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Hot flushes 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Nausea 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Nausea 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Panic attack 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Vomiting 1.6%
Disc. AE
15 mg 2 times / day single, oral (mean)
Recommended
Dose: 15 mg, 2 times / day
Route: oral
Route: single
Dose: 15 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
healthy, mean age 30 years
n = 61
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Population Size: 61
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Anger 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Anxiety 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Depression 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Fatigue 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Hypomania 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Lethargy 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Migraine 1.5%
Disc. AE
12.5 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 12.5 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12.5 mg, 2 times / day
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
unhealthy, median age 9 years
n = 65
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorders
Age Group: median age 9 years
Sex: M+F
Population Size: 65
Sources: Page: nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Letter: Methylphenidate reaction.
1975 Jun
Synthesis and pharmacology of site specific cocaine abuse treatment agents: a new synthetic methodology for methylphenidate analogs based on the Blaise reaction.
2001 Apr
Toward individualized evidence-based medicine: five "N of 1" trials of methylphenidate in geriatric patients.
2001 Apr
Pharmacotherapeutic management of autism.
2001 Apr
Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder.
2001 Apr
An adolescent who abruptly stops his medication for attention-deficit hyperactivity disorder.
2001 Apr
Understanding Rx options for the youngest patients.
2001 Aug
Concerns about Ritalin.
2001 Aug
Rewarding properties of methylphenidate: sensitization by prior exposure to the drug and effects of dopamine D1- and D2-receptor antagonists.
2001 Aug
[Methylphenidate therapy in 141 patients with hyperkinetic disorder or with pervasive developmental disorder and hyperkinesia].
2001 Jul
A comparison of the visual symptoms between ADD/ADHD and normal children.
2001 Jul
Stimulant drugs for severe hyperactivity in childhood.
2001 Jul
Rehabilitative management of post-stroke visuospatial inattention.
2001 Jul 10
Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: a pilot study.
2001 Jul-Aug
Correlations between motor persistence and plasma levels in methylphenidate-treated boys with ADHD.
2001 Jun
Advances in paediatric neuropsychopharmacology: an overview.
2001 Jun
Adult ADHD. Controlled medication assessment.
2001 Jun
Effect of repeated methylphenidate administration on presynaptic dopamine and behaviour in young adult rats.
2001 Jun
Comparison in symptoms between aged and younger patients with narcolepsy.
2001 Jun
The development of selective attention in children with attention deficit hyperactivity disorder.
2001 Jun
Attention deficit hyperactivity disorder and substance use disorders: Is there a causal link?
2001 Jun
Effects of TENS and methylphenidate in tuberculous meningo-encephalitis.
2001 Jun
Explosive outbursts associated with methylphenidate.
2001 Jun
Managing stimulant medication for attention-deficit/hyperactivity disorder.
2001 Jun
Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
2001 Jun
Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans.
2001 Jun
Practice parameters for the treatment of narcolepsy: an update for 2000.
2001 Jun 15
Commentary on Greene and Ablon: What does the MTA study tell us about effective psychosocial treatment for ADHD?
2001 Mar
Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review.
2001 Mar
A strategy for removing the bias in the graphical analysis method.
2001 Mar
alpha(2C)-Adrenoceptors modulate the effect of methylphenidate on response rate and discrimination accuracy in an operant test.
2001 Mar 15
[Prescription of central nervous system stimulants].
2001 Mar 20
[Neuropsychological follow-up of attention deficit/hyperactive disorder in adulthood before and after treatment with methylphenidate].
2001 May
Short-term cardiovascular effects of methylphenidate and adderall.
2001 May
Psychostimulants in preschool children with attention-deficit/hyperactivity disorder: clinical evidence from a developmental disorders institution.
2001 May
An auditable protocol for treating attention deficit/hyperactivity disorder.
2001 May
Methylphenidate sensitization is modulated by valproate.
2001 May 25
[Is Ritalin prescribed insufficiently to hyperactive children in Nordland?].
2001 May 30
Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study.
2001 May-Jun
Gilles de la Tourette Syndrome.
2001 May-Jun
Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications.
2001 May-Jun
Methylphenidate improves HIV-1-associated cognitive slowing.
2001 Spring
Methylphenidate in stimulants abuse: three case reports.
2001 Spring
Retrospective comparison of Adderall and methylphenidate in the treatment of attention deficit hyperactivity disorder.
2001 Spring
Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters.
2001 Spring
Can methylphenidate facilitate sleep in children with attention deficit hyperactivity disorder?
2001 Spring
Methylphenidate augmentation of citalopram in elderly depressed patients.
2001 Summer
Myoclonus during prolonged treatment with sertraline in an adolescent patient.
2001 Summer
Pharmacokinetic interactions between cyclosporine and bupropion or methylphenidate.
2001 Summer
Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology.
2001 Summer
Patents

Sample Use Guides

Administer in divided doses 2 or 3 times daily, preferably 30 to 45 minutes before meals. Average dosage is 20 to 30 mg daily. Some patients may require 40 to 60 mg daily. In children the starting dose is 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly.
Route of Administration: Oral
Murine neural stem cells were treated directly after seeding to the cover-slip using different concentration (0 nM, 1 nM, 10 nM, 100 nM) of methylphenidate. The drug was found to enhance neuronal differentiation and inhibit neural proliferation.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:39:04 GMT 2023
Edited
by admin
on Fri Dec 15 15:39:04 GMT 2023
Record UNII
4B3SC438HI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHYLPHENIDATE HYDROCHLORIDE
EP   JAN   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
Common Name English
METHYLIN
Brand Name English
QUILLIVANT
Brand Name English
APTENSIO
Brand Name English
QUILLICHEW
Brand Name English
Methyl α-phenyl-2-piperidineacetate hydrochloride
Systematic Name English
Methylphenidate hydrochloride [WHO-DD]
Common Name English
CONCERTA
Brand Name English
JORNAY PM
Brand Name English
METHYLPHENIDATE HCL
Common Name English
METHYLPHENIDATE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
METADATE
Brand Name English
METHYLPHENIDATE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
METHYLPHENIDATE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
SPD-544
Code English
EQUASYM
Brand Name English
METHYLPHENIDATE HYDROCHLORIDE [MART.]
Common Name English
FOQUEST
Brand Name English
APTENSIO XR
Brand Name English
METADATE CD
Brand Name English
SPD544
Code English
METHYLPHENIDATE HYDROCHLORIDE [VANDF]
Common Name English
METHYLPHENIDATE HYDROCHLORIDE CII [USP-RS]
Common Name English
NSC-169868
Code English
OROS MPH
Common Name English
EQUASYM XL
Brand Name English
ADHANSIA XR
Brand Name English
METHYLPHENIDATE HYDROCHLORIDE [MI]
Common Name English
METHYLPHENIDATE HYDROCHLORIDE [JAN]
Common Name English
2-PIPERIDINEACETIC ACID, .ALPHA.-PHENYL-, METHYL ESTER, HYDROCHLORIDE, (R*,R*)-(±)-
Common Name English
RITALIN
Brand Name English
METADATE ER
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C47795
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
Code System Code Type Description
EVMPD
SUB03254MIG
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY
DAILYMED
4B3SC438HI
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY
ECHA (EC/EINECS)
206-065-3
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY
DRUG BANK
DBSALT000117
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY
CAS
298-59-9
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
NON-SPECIFIC STEREOCHEMISTRY
RXCUI
203188
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C646
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY
NSC
169868
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY
ChEMBL
CHEMBL796
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY
CHEBI
31836
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY
EPA CompTox
DTXSID8020886
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY
PUBCHEM
154100
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY
SMS_ID
100000090133
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY
CAS
23655-65-4
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY
RS_ITEM_NUM
1433008
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY
FDA UNII
4B3SC438HI
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY
MERCK INDEX
m7453
Created by admin on Fri Dec 15 15:39:04 GMT 2023 , Edited by admin on Fri Dec 15 15:39:04 GMT 2023
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY